Healthpeak Properties (DOC) Stock Still Looks Like A Bargain As Shares Climb 39%

Healthpeak Properties has delivered a solid 38.6% gain over the past three years, which puts a spotlight on whether the current US$19.97 share price is fully supported by the cash the business can generate. For anyone looking at the real estate investment trust space, the immediate question is how well Healthpeak Properties' market value lines up with the strength and timing of its future cash flows.

• The 38.6% return over three years means long term holders now need to ask if that performance is matched by the underlying stream of cash Healthpeak Properties can produce.
• As a real estate investment trust that depends on rental income and asset recycling, the way Healthpeak Properties converts those rents into steady, distributable cash may shape how secure its current valuation feels.
• If you'd rather focus on earnings, this one's for you. See why Healthpeak Properties's 56.7x P/E tells a different valuation story.

The issue now is whether Healthpeak Properties' current share price is justified by its cash flows when assessed against an intrinsic value estimate based on Discounted Cash Flow.

If you want a broader feel for how other businesses price in future cash flows, compare Healthpeak Properties with 31 high quality undervalued stocks.

Does Healthpeak Properties Look Undervalued on Cash Flow?

The Discounted Cash Flow model here uses Healthpeak Properties' adjusted funds from operations to estimate what its future cash could be worth today. Over the last twelve months, the trust produced about $1.29b of free cash flow, which gives the model a sizeable current cash base to work from.

Analysts and longer term estimates in this DCF assume that free cash flow broadly grows from around today’s level, with projected annual figures moving higher into the next decade rather than falling away. On those assumptions, the DCF output points to an estimated intrinsic value that sits substantially above the current $19.97 share price, which suggests the market is pricing Healthpeak Properties more cautiously than the cash flow stream implies. Find out what Healthpeak Properties could be worth using our Discounted Cash Flow (DCF) estimate.

The Healthpeak Properties Narrative: What Would Justify Today's Price?

Narratives for Healthpeak Properties pick up where the valuation puzzle leaves off and explain which future paths for growth, profitability and earnings would need to play out for the stock to be worth materially more or materially less than its current price, all housed on Simply Wall St's Community page. Each view connects its valuation number to a specific expectation for how Healthpeak Properties' growth, margins and risk profile might evolve, which you can revisit as new information comes through.

Community views on Healthpeak Properties pull in opposite directions, with one side seeing upside from structural demand and the other focused on earnings risk.

Bull case: 13% undervalued

"Continued execution on operating efficiencies, including the internalization of property management and the rollout of advanced data/AI platforms, should drive margin expansion by reducing overhead…"

Discover why this Narrative puts Healthpeak Properties at 13% undervalued.

Bear case: 11% overvalued

"The company faces a risk of continued occupancy declines and tenant credit issues within its life science portfolio, as a meaningful portion of tenants are highly dependent on the capital markets…"

Explore why this Narrative puts Healthpeak Properties at 11% overvalued.

For Healthpeak Properties, price is just one side of the decision

Valuation only captures part of the picture for Healthpeak Properties, since separate checks have highlighted potential pressure points that deserve a closer look before you commit fresh capital. Take a closer look at 4 warning signs (2 major) before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com